​

Verastem (VSTM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

VSTM Stock Forecast

Verastem (VSTM) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $14.00 and a low of $10.00. This represents a 109.06% increase from the last price of $5.74.

- $3 $6 $9 $12 $15 High: $14 Avg: $12 Low: $10 Last Closed Price: $5.74

VSTM Stock Rating

Verastem stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (73.68%), 5 Hold (26.32%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 5 14 Strong Sell Sell Hold Buy Strong Buy

VSTM Price Target Upside V Benchmarks

TypeNameUpside
StockVerastem109.06%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts224
Avg Price Target$12.00$12.00$11.00
Last Closing Price$5.74$5.74$5.74
Upside/Downside109.06%109.06%91.64%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2526---8
Mar, 2526---8
Feb, 2526---8
Jan, 2526---8
Dec, 2427---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 24, 2025Michael SchmidtGuggenheim$14.00$6.88103.49%143.90%
Jul 29, 2024Graig SuvannavejhMizuho Securities$7.00$2.77152.71%21.95%
May 24, 2024Justin ZelinBTIG$13.00$4.12215.53%126.48%
Apr 15, 2022Gregory RenzaRBC Capital$5.00$1.77182.49%-12.89%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 24, 2025GuggenheimBuyBuyhold
Jan 07, 2025RBC CapitalOutperformOutperformhold
Dec 31, 2024BTIGBuyBuyhold
Sep 30, 2024GuggenheimBuyinitialise
May 28, 2024RBC CapitalOutperformOutperformhold
Jun 15, 2023Mizuho SecuritiesPositiveBuyupgrade
Jun 15, 2023CitigroupBuyupgrade
Jun 15, 2023Mizuho SecuritiesPositiveupgrade
Apr 26, 2022Zacks Investment ResearchHoldupgrade
Apr 14, 2022RBC CapitalOutperforminitialise

Financial Forecast

EPS Forecast

$-20 $-15 $-10 $-5 $0 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.30$-5.58$-4.58$-3.96$-3.66----
Avg Forecast$-4.86$-4.76$-4.71$-3.14$-3.03$-2.57$-1.56$-0.53$1.11
High Forecast$-2.11$-2.07$-0.12$-3.14$-2.90$-2.20$0.34$3.83$3.55
Low Forecast$-12.46$-12.20$-15.14$-3.15$-3.13$-2.84$-3.02$-4.79$0.03
Surprise %9.05%17.23%-2.76%26.11%20.79%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$88.52M$2.05M$2.60M-$10.00M----
Avg Forecast$54.61M$1.47M$2.66M$5.93M$7.70M$22.94M$94.46M$199.00M$376.45M
High Forecast$120.29M$3.24M$7.20M$16.01M$20.78M$36.20M$94.46M$537.11M$1.02B
Low Forecast$30.88M$830.87K$668.98K$1.49M$1.93M$9.66M$94.46M$49.89M$94.38M
Surprise %62.10%39.72%-2.55%-29.87%----

Net Income Forecast

$-350M $-260M $-170M $-80M $10M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-67.73M$-81.10M$-73.85M$-87.37M$-130.64M----
Avg Forecast$-107.18M$-104.98M$-103.90M$-69.34M$-66.52M$-55.51M$-29.63M$19.53M$24.37M
High Forecast$-46.64M$-45.68M$-2.75M$-69.16M$-63.97M$-48.46M$7.41M$84.36M$78.19M
Low Forecast$-274.78M$-269.12M$-333.99M$-69.53M$-69.06M$-62.55M$-66.67M$-105.59M$631.46K
Surprise %-36.81%-22.75%-28.92%25.99%96.39%----

VSTM Forecast FAQ

Is Verastem stock a buy?

Verastem stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Verastem is a favorable investment for most analysts.

What is Verastem's price target?

Verastem's price target, set by 19 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $10 at the low end to $14 at the high end, suggesting a potential 109.06% change from the previous closing price of $5.74.

How does Verastem stock forecast compare to its benchmarks?

Verastem's stock forecast shows a 109.06% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Verastem over the past three months?

  • April 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Verastem’s EPS forecast?

Verastem's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.57, marking a -29.78% decrease from the reported $-3.66 in 2024. Estimates for the following years are $-1.56 in 2026, $-0.53 in 2027, and $1.11 in 2028.

What is Verastem’s revenue forecast?

Verastem's average annual revenue forecast for its fiscal year ending in December 2025 is $22.94M, reflecting a 129.42% increase from the reported $10M in 2024. The forecast for 2026 is $94.46M, followed by $199M for 2027, and $376.45M for 2028.

What is Verastem’s net income forecast?

Verastem's net income forecast for the fiscal year ending in December 2025 stands at $-55.507M, representing a -57.51% decrease from the reported $-131M in 2024. Projections indicate $-29.633M in 2026, $19.53M in 2027, and $24.37M in 2028.